WALSH COLIN

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings by this filer, out of 64. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

5 of 64
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
Attovia Therapeutics, Inc.—Open-market buy$121,8885,744 sharesAug 28, 2026Attovia Therapeutics, Inc.$121,888Buy · Aug 28Open-market buy5,744Aug 28, 2026
Attovia Therapeutics, Inc.—Open-market buy$242,43511,398 sharesAug 28, 2026Attovia Therapeutics, Inc.$242,435Buy · Aug 28Open-market buy11,398Aug 28, 2026
Attovia Therapeutics, Inc.—Open-market buy$969,65745,588 sharesAug 28, 2026Attovia Therapeutics, Inc.$969,657Buy · Aug 28Open-market buy45,588Aug 28, 2026
Attovia Therapeutics, Inc.—Open-market buy$243,77511,488 sharesAug 28, 2026Attovia Therapeutics, Inc.$243,775Buy · Aug 28Open-market buy11,488Aug 28, 2026
Attovia Therapeutics, Inc.—Open-market buy$609,37528,717 sharesAug 28, 2026Attovia Therapeutics, Inc.$609,375Buy · Aug 28Open-market buy28,717Aug 28, 2026